Endoscope-Guided Interstitial Intensity-Modulated Brachytherapy and Intracavitary Brachytherapy as Boost Radiation for Primary Early T Stage Nasopharyngeal Carcinoma
Background Intracavitary brachytherapy (ICBT) is usually applied as boost radiotherapy for superficial residual of nasopharyngeal carcinoma (NPC) after primary extern-beam radiptherapy (ERT). Here, we evaluated the outcome of endoscope-guided interstitial intensity-modulated brachytherapy (IMBT) boost radiation for deep-seated residual NPC. Methodology/Principal Findings Two hundred and thirteen patients with residual NPC who were salvaged with brachytherapy boost radiation during 2005–2009 were analyzed retrospectively. Among these patients, 171 patients had superficial residual NPC (≤1 cm below the nasopharyngeal epithelium) were treated with ICBT boost radiation, and interstitial IMBT boost radiation was delivered to 42 patients with deep-seated residual NPC (>1 cm below the nasopharyngeal epithelium). We found that IMBT boost subgroup had a higher ratio of T2b (81.0% VS 34.5%, P<0.001) and stage II (90.5% VS 61.4%, P = 0.001) than that of ICBT boost subgroup. The dosage of external-beam radiotherapy in the nasopharyngeal (63.0±3.8 VS 62.6±4.3 Gray (Gy), P = 0.67) and regional lymph nodes (55.8±5.0 VS 57.5±5.7 Gy, P = 0.11) was comparable in both groups. For brachytherapy, IMBT subgroup had a lower boost radiation dosage than ICBT subgroup (11.0±2.9 VS 14.8±3.2 Gy, P<0.01). Though the IMBT group had deeper residual tumors and received lower boost radiation dosages, both subgroups had the similar 5-year actuarial overall survival rate (IMBT VS ICBT group: 96.8% VS 93.6%, P = 0.87), progression-free survival rate (92.4% VS 86.5%, P = 0.41) and distant metastasis-free survival rate (94.9% VS 92.7%, P = 0.64). Moreover, IMBT boost radiation subgroup had a similar local (97.4% VS 94.4%, P = 0.57) and regional (95.0% VS 97.2%, P = 0.34) control to ICBT subgroup. The acute and late toxicities rates were comparable between the both subgroups. Conclusions/Significance IMBT boost radiation may be a promising therapeutic selection for deep-seated residual NPC.
References
[1]
Chan AT (2011) Current treatment of nasopharyngeal carcinoma. Eur J Cancer 47 Suppl 3S302–303. doi: 10.1016/s0959-8049(11)70179-4
[2]
Lee AW, Fee WE Jr, Ng WT, Chan LK (2012) Nasopharyngeal carcinoma: salvage of local recurrence. Oral Oncol 48: 768–774. doi: 10.1016/j.oraloncology.2012.02.017
[3]
Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, et al. (2005) Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 23: 3568–3576. doi: 10.1200/jco.2005.02.147
[4]
Schinagl DA, Marres HA, Kappelle AC, Merkx MA, Pop LA, et al. (2010) External beam radiotherapy with endocavitary boost for nasopharyngeal cancer: treatment results and late toxicity after extended follow-up. Int J Radiat Oncol Biol Phys 78: 689–695. doi: 10.1016/j.ijrobp.2009.08.072
[5]
Stoker SD, van Diessen JN, de Boer JP, Karakullukcu B, Leemans CR, et al. (2013) Current treatment options for local residual nasopharyngeal carcinoma. Curr Treat Options Oncol 14: 475–491. doi: 10.1007/s11864-013-0261-5
[6]
Wang CC (1991) Improved local control of nasopharyngeal carcinoma after intracavitary brachytherapy boost. Am J Clin Oncol 14: 5–8. doi: 10.1097/00000421-199102000-00002
[7]
Sultanem K, Shu HK, Xia P, Akazawa C, Quivey JM, et al. (2000) Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 48: 711–722. doi: 10.1016/s0360-3016(00)00702-1
[8]
Wu J, Guo Q, Lu JJ, Zhang C, Zhang X, et al. (2013) Addition of intracavitary brachytherapy to external beam radiation therapy for T1–T2 nasopharyngeal carcinoma. Brachytherapy 12: 479–486. doi: 10.1016/j.brachy.2012.10.004
[9]
Leung TW, Wong VY, Sze WK, Lui CM, Tung SY (2008) High-dose-rate intracavitary brachytherapy boost for early T stage nasopharyngeal carcinoma{private}. Int J Radiat Oncol Biol Phys 70: 361–367. doi: 10.1016/j.ijrobp.2007.06.078
[10]
Ren YF, Cao XP, Xu J, Ye WJ, Gao YH, et al. (2013) 3D-image-guided high-dose-rate intracavitary brachytherapy for salvage treatment of locally persistent nasopharyngeal carcinoma. Radiat Oncol 8: 165. doi: 10.1186/1748-717x-8-165
[11]
Leung TW, Tung SY, Sze WK, Sze WM, Wong VY, et al. (2000) Salvage radiation therapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 48: 1331–1338. doi: 10.1016/s0360-3016(00)00776-8
[12]
Teo PM, Kwan WH, Chan AT, Lee WY, King WW, et al. (1998) How successful is high-dose (> or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys 40: 897–913. doi: 10.1016/s0360-3016(97)00854-7
[13]
Lee AW, Foo W, Law SC, Poon YF, Sze WM, et al. (1997) Reirradiation for recurrent nasopharyngeal carcinoma: factors affecting the therapeutic ratio and ways for improvement. Int J Radiat Oncol Biol Phys 38: 43–52. doi: 10.1016/s0360-3016(97)00244-7
[14]
Chua DT, Sham JS, Kwong DL, Wei WI, Au GK, et al. (1998) Locally recurrent nasopharyngeal carcinoma: treatment results for patients with computed tomography assessment. Int J Radiat Oncol Biol Phys 41: 379–386. doi: 10.1016/s0360-3016(98)00063-7
[15]
Huang EY, Sun LM, Lin H, Lan JH, Chanchien CC, et al. (2013) A prospective cohort study to compare treatment results between 2 fractionation schedules of high-dose-rate intracavitary brachytherapy (HDR-ICBT) in patients with cervical cancer. Int J Radiat Oncol Biol Phys 85: 123–128. doi: 10.1016/j.ijrobp.2012.03.045
[16]
Nomden CN, de Leeuw AA, Roesink JM, Tersteeg RJ, Moerland MA, et al. (2013) Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience. Radiother Oncol 107: 69–74. doi: 10.1016/j.radonc.2013.04.006
[17]
Greene FL PD, Fleming ID, Fritz AG Balch CM. (2002) AJCC cancer staging handbook from the AJCC cancer staging manual. (6th ed)Springer, New York: 73–81.
[18]
Palmer AL, Di Pietro P, Alobaidli S, Issa F, Doran S, et al. (2013) Comparison of methods for the measurement of radiation dose distributions in high dose rate (HDR) brachytherapy: Ge-doped optical fiber, EBT3 Gafchromic film, and PRESAGE(R) radiochromic plastic. Med Phys 40: 061707. doi: 10.1118/1.4805100
[19]
Teo PM, Leung SF, Lee WY, Zee B (2000) Intracavitary brachytherapy significantly enhances local control of early T-stage nasopharyngeal carcinoma: the existence of a dose-tumor-control relationship above conventional tumoricidal dose. Int J Radiat Oncol Biol Phys 46: 445–458. doi: 10.1016/s0360-3016(99)00326-0
[20]
Chen MY, Cao XP, Sun R, Hua YJ, Li AJ, et al. (2007) [Application of interstitial brachytherapy via parapharynx involvement transnasal approach to enhance dose in radiotherapy for nasopharyngeal carcinoma]. Ai Zheng 26: 513–518.
[21]
Leung TW, Tung SY, Wong VY, Sze WK, Lui CM, et al. (2005) Nasopharyngeal intracavitary brachytherapy: the controversy of T2b disease. Cancer 104: 1648–1655. doi: 10.1002/cncr.21371
[22]
Ren YF, Gao YH, Cao XP, Ye WJ, Teh BS (2010) 3D-CT implanted interstitial brachytherapy for T2b nasopharyngeal carcinoma. Radiat Oncol 5: 113. doi: 10.1186/1748-717x-5-113
[23]
Shi C, Guo B, Cheng CY, Esquivel C, Eng T, et al. (2010) Three dimensional intensity modulated brachytherapy (IMBT): dosimetry algorithm and inverse treatment planning. Med Phys 37: 3725–3737. doi: 10.1118/1.3456598
[24]
Das RK, Patel R, Shah H, Odau H, Kuske RR (2004) 3D CT-based high-dose-rate breast brachytherapy implants: treatment planning and quality assurance. Int J Radiat Oncol Biol Phys 59: 1224–1228. doi: 10.1016/j.ijrobp.2004.03.030
[25]
Kovacs G, Melchert C, Sommerauer M, Walden O (2007) Intensity modulated high-dose-rate brachytherapy boost complementary to external beam radiation for intermediate- and high-risk localized prostate cancer patients—how we do it in Lubeck/Germany. Brachytherapy 6: 142–148. doi: 10.1016/j.brachy.2007.02.062
